Guidance to applicants Submission of Marketing Authorisation Applications



Similar documents
REQUIREMENTS FOR NATIONAL AND MUTUAL RECOGNITIONS VMP APPLICATIONS

INFARMED S Electronic System for the Management of Medicinal Products of Human Use (SMUH ALTER) Submission of Variation Applications

Instructions to applicants for submitting variations to the terms of Marketing Authorisations

External User Manual. Portal for Submission of Applications for the Update of the Manufacturing Flowchart as registered in INFARMED I.P.

External User Manual. Online Registration of Users of the Electronic System for the Management of Medicinal Products of Human Use of INFARMED, I.P.

Pharmacovigilance System Master File (PSMF), QPPV and audits

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. June 2013

Regulatory approval routes in the European System for Medicinal Products

MRP & DCP step by steb instructions how to apply and how the procedures are conducted

Harmonised Technical Guidance for ectd Submissions in the EU

LICENCE FEES FOR MEDICINAL PRODUCTS FOR HUMAN USE ONLY PROPOSALS FOR APRIL 2002

A 4.5 Validity Period of a Marketing Authorisation

Marketing Authorization Procedures in the European Union Making the Right Choice

ONSITE TRACK EASY Campbell Arnott s Contractor Management Portal Portal User Guide: Employee Registration & Induction Bookings

Report from the CMDh meeting held on September !!! 3 months to go until the mandatory use of the electronic application form!!!

PROXY DELEGATION AND VOTING BY REMOTE MEANS OF COMMUNICATION

GUIDANCE for Administration of the Sunset Clause

Guidelines. of

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

INSTRUCTIONS FOR FILING A CONDOMINIUM / COOPERATIVE COMPLAINT

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2

A critical review of the current. marketing authorisation transfer procedure. in Europe

CMDv/BPG/001. BEST PRACTICE GUIDE for Veterinary Mutual Recognition Procedure (MRP) Edition 04. Edition date: 19 July 2013

(ACCORDINGLY TO ARTICLE 11º OF DECREE-LAW N.º 145/2009) INTRODUCTION page 2. ACESS TO THE SYSTEM page 3. NOTIFICATION MANAGEMENT page 4

The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation

Regulation of clinical trials with medicinal products: Where are we now?

Guide to Fees for Veterinary Products

Chapter 1 GENERAL INTERPRETATION

esubmission Guidelines

.ME. Rules for Uniform Domain Name Dispute Resolution Policy (the "Rules") (As approved by domen on November 13, 2015)

Title: Mr Mrs Ms Others... Family Name (in block letters):... First Names (in block letters):... NIC No:...Nationality:...

VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005

BASIC BANK ACCOUNTS. Lisbon,

Wits Vendor Onboarding Suppliers Tutorial Table of Contents

Draft agreed by the QWP February Draft adopted by the CHMP for release for consultation March Draft endorsed by the CMD(h) March 2015

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Questions & answers on signal management

Bank or building society account details form

training programme in pharmaceutical medicine Regulatory affairs

Manual Registration in the *SRE

BEST PRACTICE GUIDE for Handling of Periodic Safety Update Reports

EARLY CALL FOR REGISTRATION FOR UNIVERSITY DOCTORAL STUDIES (PhD) FOR STUDENTS WITH NON-EHEA QUALIFICATIONS. ACADEMIC YEAR

ARTICLES OF ASSOCIATION OF

A Guide to the Wellcome Trust Grant Application & Management System (WT Grant Tracker )

Notification No. 3/2012 [F. No. 142/27/2011-SO (TPL)], dated

Online Banking Agreement & Disclosure

Recognition of Prior Learning, Credit Transfer and National Recognition Policy

Official Journal of the European Union. (Acts whose publication is obligatory)

LEGAL FRAMEWORK OF BASIC BANK ACCOUNTS

The EU portal and database

PLANT VARIETIES PROTECTION ACT (CHAPTER 232A, SECTION 54) PLANT VARIETIES PROTECTION RULES

European Code of Conduct on Data Centre Energy Efficiency

VCB-MONEY SERVICE PROVISION CONTRACT

VETERINARY MEDICINE LICENSE APPLICATION INSTRUCTIONS AND INFORMATION

Quick Response (QR) codes in the labelling and package leaflet of centrally authorised 1 medicinal products

Air Traffic Service Training Providers Entry Control Procedures Manual 3. Sample Documents

USER MANUAL FOR NEW VENDOR. SEHA Online Vendor Registration Project REGISTRATION -ONLINE. Creation Date: 01-Apr-15 Last Updated: 15-Apr-15 Version: 2

Guideline on good pharmacovigilance practices (GVP)

1 ) LOCATION OF EXECUSION, DESCRIPTION

Pledged Cash Account Agreement

Web Hosting Agreement & Terms

PROXY / REPRESENTATIVE CARD. Particulars of Shareholder

PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING

NUCLEUS CONNECT PTE. LTD. INTERCONNECTION OFFER (ICO) AGREEMENT SERVICE SCHEDULE L3 VIRTUAL ROUTING DOMAIN SETUP SERVICE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

The Clinical Trials Regulation EU No 536/2014: and Phase I trials

ANNOUNCEMENT ON CONVENING AN ORDINARY GENERAL MEETING OF GIEŁDA PAPIERÓW WARTOŚCIOWYCH W WARSZAWIE S.A. (WARSAW STOCK EXCHANGE)

White Paper The EU Clinical Trials Regulation Main Changes and Challenges

Under the terms of Article 161c of the Constitution, the Assembly of the Republic hereby decrees the following: Chapter I GENERAL PROVISIONS

Rules for Uniform Domain Name Dispute Resolution Policy (the "Rules") As approved by the ICANN Board of Directors on 30 October 2009.

INSTITUTE OF ART, DESIGN AND ENTERPRISE - UNIVERSITY

End of consultation (deadline for comments) 14 October Adoption by Committee for advanced therapies 15 October 2010

COUNCIL OF MINISTERS DECREE LAW 17/09 OF 26 JUNE

Mutual recognition between the EU member states: official framework for collaboration saves resources?

S.I. No.74 of 2007 REGULATIONS. entitled NON-LIFE INSURANCE (PROVISION OF INFORMATION)(RENEWAL OF POLICY OF INSURANCE) REGULATIONS 2007

Draft agreed by the QWP February Draft adopted by the CHMP for release for consultation March Draft endorsed by the CMD(h) March 2015

ASBESTOS REMOVAL LICENCE ASBESTOS NOTIFICATIONS


THE LAND REGISTRY E-ALERT SERVICE - APPLICATION FOR CHANGE OF PARTICULARS

Azerbaijan Law on Mortgage (adopted on 3 July, 1998; entered into force on 19 August 1998)

FREQUENTLY ASKED QUESTIONS (FAQs) ON e-filing OF TAX AUDIT REPORT

Certification Procedure of RSPO Supply Chain Audit

Invitation to tender Outsourcing of tasks related to receipt of Schengen visa applications in Egypt

AGREEMENT ON TECHNICAL BARRIERS TO TRADE. Having regard to the Uruguay Round of Multilateral Trade Negotiations;

European Code of Conduct on Data Centre Energy Efficiency

APPLICATION TO OPEN AN ACCOUNT COMPANY / NGO / EMBASSY / GOVERNMENT / REGISTERED ASSOCIATION

Fair Registration Practices Report

Format of Board Resolution to be submitted by the Company along with the SBI FAST (CMP Internet Portal) Registration Form

College ter Beoordeling van Geneesmiddelen

Transcription:

Guidance to applicants Submission of Marketing Authorisation Applications The purpose of this notice to applicants is to clarify aspects related with the submission to Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., of Marketing Authorisation Applications (MAAs) by national procedure (NP), and by Mutual Recognition and Decentralised procedure (MRP/DCP). It should be used as a supplement to the Decree Law no. 176/2006 of 30 August, in its current wording, that establishes the legal regimen that regulates the marketing authorization of medicinal products for human use. The Decree Law no. 176/2006 of 30 August, in its current wording lays down the content of the dossier for MAA by NP and by MRP/DCP, and the checklists published by Infarmed in Página Inicial> Medicamentos Uso Humano> Autorização de Introdução no Mercado> Procedimentos de AIM are supporting documents to the correct submission of applications. The applicants are advised to carefully read the information provided in the electronic pages of Infarmed and CMDh to properly prepare a submission. Applicants of MAAs by NP and MRP/DCP should submit the dossier to Infarmed only after electronic pre-submission of the application in the portal Medicinal Products for Human Use Management System MAA (SMUH-AIM). This document does not cover the simplified registration of homeopathic medicinal products, traditional herbal medicinal products and allergen products. 1/8

Contents 1. Electronic pre-submission of MAA and payment of fee...3 1.1. Instructions for payment of the applicable fees...3 2. Submission of MAA to Infarmed...3 3. User registration...4 4. Exclusive use of electronic communications...4 Annex I Provisions applicable only to National Procedure...6 Annex II Declaration form for the use of e-mail communications with Infarmed...8 2/8

1. Electronic pre-submission of MAA and payment of fee All MAA by NP and by MRP/DCP, including MRP or RUP with Portugal as RMS (for which preparation of the assessment report by the RMS is required previously to the European procedure) must be presubmitted in the portal SMUH-AIM, available in the Infarmed website, before the submission of the dossier to Infarmed. The issuing of the payment form with the reference for payment is performed using automatic calculation rules applied to the information in the online form, therefore applicants should consider the need to fill the form appropriately. Applicants should pay the amount discriminated using the indicated payment details. Applicants are advised to carefully read the Instructions Manual of the portal SMUH-AIM, available in the same area of the Infarmed website, to ensure that applications are properly pre-submitted and to streamline their validation. 1.1. Instructions for payment of the applicable fees The payment of fees applicable to MAAs is integrated in the new SMUH-AIM portal. The issuing of the payment form is made by the applicant in the electronic platform after correct filling of the electronic application(s) form(s), and the fee is calculated by automatic calculation rules according to the information in this(ese) online form(s). After issuing the payment form, the applicant must issue the reference for payment and subsequently pay the amount discriminated using the payment details indicated. In addition, for applicants paying fees from the national territory, the payment will only be available via Multibanco (ATM) reference. Applicants are advised to carefully read the Instructions Manual of the portal SMUH-AIM, available in the same area of the Infarmed website, to ensure the correct issue of the payment form and of the payment reference. 2. Submission of MAA to Infarmed The MAA (i.e. the dossier) should only be submitted to Infarmed after electronic pre-submission in the portal SMUH-AIM and validation of payment of fee by Infarmed The applicant should confirm validation of fee payment in the portal by checking the status Payment of fee valid, usually between 1-3 working days after paying the fee. The electronic pre-submission in the portal SMUH-AIM can be made as far ahead as deemed necessary, in order to not to restrict the formal submission of the application to Infarmed in the desired date. 3/8

The submission of the application to Infarmed may be made: sent: By post mail The documentation should be sent to: Submission of MAA-NP or Submission of MAA- MRP/DCP (as applicable) Centro de Comunicação e Atendimento INFARMED I.P. Parque da Saúde de Lisboa Av. do Brasil, n.º 53 Pavilhão 24 1749-004 Lisboa On-site at Infarmed The documentation should be delivered on-site to Infarmed at Pavilhão 24, Parque de Saúde de Lisboa - Avenida do Brasil, 53. The cover letter should mention in the subject MAA-NP (for national procedures) or MAA-MRP/DCP (for mutual Recognition and decentralised procedures). In both situations, the submission of the documentation, by itself, does not determine the validation of the application. The application submitted will be analyzed to verify its compliance with legal, technical and procedural requirements. The validation of MAA by national procedure is described in Annex I. 3. User registration For each applicant / proposed MA holder, Infarmed assigns only one user and one password to access SMUH-AIM. To request access (user and/or password), applicants / proposed MA holders should go to the User Registration platform at the Infarmed website, accept the terms of use, properly fill in the request form and included mandatory documentation. The User Registration Manual available in the same area of the Infarmed website should be consulted. 4. Exclusive use of electronic communications According to article 9 of the Decree Law no. 176/2006 of 30 August, in its current wording, concerning probative value of electronic communications, and with a view to streamlining communications between Infarmed and applicants with regard to validation, starting of the assessment, requests for further information and notification of the end of procedure (if applicable), the Medicinal Product Evaluation Department (DAM) will make communications exclusively by email. 4/8

The email addresses used by Infarmed where to applicants should send all correspondence are: Procedure Type MAAs by National procedure (NP) MAAs by MRP/DCP with Portugal as CMS MAAs by MRP/DCP with Portugal as RMS Infarmed e-mail addresses aim.nacional@infarmed.pt cms.procedures@infarmed.pt rms.procedures@infarmed.pt The notification of the decision on MAAs with MAA certificate will continue to be sent by post mail. At the time of electronic pre-submission of MAA, the document Declaration form for the use of e-mail communications with Infarmed must be attached, identifying the applicant s e-mail address for Infarmed to send its communications. The attached form for this declaration (Annex II) should be filled in, bearing in mind the following: Wherever possible, the applicant should indicate a shared e-mail (proxy) for institutional communications with Infarmed. The document Declaration form for the use of e-mail communications with Infarmed should be signed by the applicant / proposed MA holder or a duly authorised representative. 5/8

Annex I Provisions applicable only to National Procedure Validation of the MAAs submitted by national procedure The validation or invalidation of the application will always be communicated to the applicant within 10 days after the formal submission of the MAA to Infarmed. Refusal of MAA The grounds for refusal are: No electronic pre-submission in the portal SMUH-AIM No payment of fee. Invalidation of MAA The grounds for invalidation are: Non compliance with the provisions of the article 15 of Decree-Law n º 176/2006 of 30 August, in its current wording. Infarmed will notify the applicant of the grounds for invalidation and return 90% of the already paid fee. The applicant has 30 days to collect the CD/DVD (if applicable), after which it will be destroyed. Validation of MAA The applicant will be notified of the validation of the application. It is possible to consult the status of a MAA by national procedure in the application Gestão de Pedidos de AIM, using the same username and password assigned for SMUH. List of questions during the assessment of MAA In order to harmonize the number of list of questions during the assessment of MAA by national procedure, as well as the target dates for the submission of the responses by applicants, Infarmed inform that: 1. Each assessor can issue two list of questions. The target dates for the submission of the responses are: - Quality and bioavailability/bioequivalence assessment: - 1st List of questions 60 days - 2nd List of questions 30 days - Non-Clinical and Clinical assessment: - 1st List of questions 30 days - 2nd List of questions 10 days 2. A third list of question is exceptional and will only be possible after authorization of the Executive Board of Infarmed. 6/8

3. Infarmed can authorize an extension of the period for response to a list of questions, at most, equal to the 1st one given to answer. Exceptionally, Infarmed can authorize a 2nd additional extension of the period for response to list of questions not exceeding half the time of the 1st. 4. In preliminary hearings no additional time to response will be allowed. 7/8

Annex II Declaration form for the use of e-mail communications with Infarmed <MA holder> <Authorized representative> <Applicant>, legal entity/taxpayer identification no. <taxpayer identification number>, with its registered office at <address>, represented herein by <name of MA holder representative>, in the capacity of <director, manager, legal representative, etc.> and duly authorised to act, hereby declares, for the purposes of the n.º 3 of article 9 of the Decree Law no. 176/2006 of 30 August, in its current wording, that all of its communications with Infarmed, I.P. relating to applications for MAs, shall be done using the following e-mail addresses: <MA holder e-mail address(es)>. Signature Date 8/8